Objective To assess adverse event (AE) resolution, delivery mode and neonatal outcomes after misoprostol or dinoprostone vaginal insert (MVI or DVI) retrieval due to AE during induction of labour (IOL).
Introduction
Cervical ripening and labour induction with prostaglandins (misoprostol or dinoprostone) are common procedures in today's obstetric practice. The overall rate of labour induction in the European Union (EU) and United States (USA) is reported to be in the range of 20-25%. 1, 2 With over 9 million births annually in these regions, at least 1.8 million women undergo labour induction. 1, 2 The majority of these women are likely to be exposed to prostaglandins, as prostaglandin methods feature prominently in the recommendations of various national guidelines.
Cochrane Pregnancy and Childbirth Group review authors with an interest in labour induction have identified five primary outcomes as being most representative of the clinically important measures of effectiveness and complications of products used for induction of labour (IOL). Four of these outcomes are directly related to safety: (i) serious neonatal morbidity and perinatal death; (ii) serious maternal morbidity or death; (iii) uterine hyperstimulation (tachysystole or hypertonus) with FHR involvement; (iv) caesarean delivery. 3 The first two outcomes, although arguably the most clinically relevant, are not precisely defined and, due to their low incidence and potential for confounding causative factors, are impractical as endpoints for clinical research in prospective trials. Sample sizes required to detect an important change in their incidences are estimated to be around 60 000 and 150 000 subjects, respectively. 4 Nevertheless, even low incidences yield substantial numbers when applied to a large population, and so remain important, not only for an individual but also from a public health perspective. In clinical research, uterine hyperstimulation with FHR involvement and caesarean deliveries are both measurable and well-recognised safety outcomes for a cervical ripening and labour induction procedure.
To support decision making and clinical management during IOL, the purpose of the current investigation is to assess the utilisation of retrieving misoprostol or dinoprostone vaginal inserts (MVI or DVI, respectively) in cases of intrapartum adverse events (AEs), including uterine hyperstimulation (referred to as uterine tachysystole) with FHR involvement and subsequent events experienced by women enrolled in the EXPEDITE trial. 5 
Methods
This investigation is a post hoc analysis of the Phase III trial, EXPEDITE (clinical trial registration at www.clinicaltrials.gov identifier NCT01127581). The primary publication contains a detailed description of the study protocol and eligible study population. 5 For a list of other investigators involved in the trial, see Appendix S1. In brief, the EXPEDITE trial was a randomised, multicentre, double-blind study conducted in the USA which compared MVI (Misodel â , Misopess â , Misodelle â , Myspess â , Ferring Pharmaceuticals) with DVI (Cervidil â , Propess â , Ferring Pharmaceuticals) for IOL in women at term gestation. MVI releases misoprostol at a mean rate of 7 microg/hour and DVI releases dinoprostone at a mean rate of 0.3 mg/hour over a period of 24 hours. 6, 7 Women enrolled into the study were pregnant at ≥36 weeks 0 days gestation; parity ≤3; baseline modified Bishop Score (mBS) ≤4; aged ≥18 years with a single, live, vertex fetus; body mass index (BMI) ≤50 kg/m 2 ; and candidates for pharmacological IOL. Women with a uterine scar or with a fetus showing signs of distress were not eligible for enrolment.
Prespecified reasons for vaginal insert retrieval
Investigators recorded the primary reason for insert retrieval as either (i) retrieval due to AE necessitating discontinuation of the study drug (these AEs were strictly defined); (ii) the retrieval of the insert at the investigator's discretion; for example, if there was an occurrence of an uterine tachysystole or category II FHR pattern event that did not qualify as an AE according to prespecified definitions; (iii) onset of active labour with prespecified definition; (iv) being in situ for 24 hours; (v) vaginal insert fell out; (vi) retrieval at maternal request or (vii) 'other' reason. Characteristics of FHR decelerations were defined according to American College of Obstetrics and Gynecology (ACOG) 8 and Macones et al. 9 Active labour was defined in line with the ACOG guidelines current at the time of the trial conduct. 10 For the current investigation, women were categorised as having the vaginal insert retrieved due to either (i) AEs (as defined previously) or for a reason other than AE, i.e. a composite of reasons (ii)-(vii) above.
Intrapartum adverse events leading to vaginal insert retrieval
The following parameters were assessed for women with the vaginal insert retrieved due to an AE: incidence of AE leading to retrieval, type of AE, time from vaginal insert administration to onset of AE and time from insert retrieval to AE resolution. Start and stop times for AEs were recorded during the trial.
Clinical outcomes
Clinical outcomes assessed were: mode of delivery (vaginal or caesarean); time from insert retrieval to delivery; incidence of low Apgar score (<7) at 5 minutes; and incidence of admission to neonatal intensive care unit (NICU). For context, these clinical outcomes are also presented for women who had either MVI or DVI retrieved for a reason other than AE by treatment group.
Statistical analysis
A two-sided Fisher's exact test was used to compare the primary reason for insert removal (difference between treatment groups in incidence of AE as primary reason for retrieval versus all other reasons) and the difference between treatment groups in the rates of NICU admission after the insert had been retrieved due to AE. A two-sided Wilcoxon rank sum test was used as a non-parametric analysis to compare time from insert administration to onset of AE and time from insert retrieval to AE resolution. A multiple logistic regression analysis was conducted to identify whether there were characteristics or baseline factors which may have predisposed women to have insert retrieval due to an AE, by regressing the insert retrieval due to an AE (Yes/No) using a backwards selection on the following regressors: induction agent (MVI versus DVI), maternal age (years), race (African-American versus other), parity (nulliparous versus parous), gestational age, baseline BMI, height, weight, induced for post-date gestation (>40 weeks), induced for maternal reason, induced for fetal reason, induced for elective reason, baseline mBS, baseline membrane status (intact versus ruptured), Group B Streptococcus-positive status and pooled sites.
Descriptive statistics including 95% confidence intervals (CIs) are provided by treatment group for the incidence of AEs and clinical maternal and neonatal outcomes for women who had MVI or DVI retrieved due to an AE or for reasons other than AEs.
Results
In all, 678 women received MVI and 680 women received DVI. The primary outcomes and the study population of the EXPEDITE trial have been published previously. 5 Primary reasons for vaginal insert retrieval Table 1 provides the primary reasons for vaginal insert retrieval. Onset of active labour was the most common reason for insert retrieval in both the MVI and DVI treatment groups. In all, 77/678 women (11.4%) in the MVI group and 27/680 (4.0%) women in the DVI group had the study drug insert removed due to an intrapartum AE (P < 0.001). The most frequent AEs leading to MVI retrieval were uterine tachysystole with FHR involvement (36/ 678 (5.3%)) and category II/III FHR pattern AE (22/678 (3.2%)). The most frequent AEs leading to DVI retrieval were category II/III FHR pattern (13/680 (1.9%)) and uterine tachysystole with FHR involvement (8/680 (1.2%)).
Subgroup baseline clinical characteristics
The subgroups were based on the primary reason for insert retrieval. The original treatment stratification of the trial was according to parity (60% nulliparous, 40% parous). Demographics and baseline characteristics of maternal age, parity, gestational age, BMI, and mBS were similar for women with the insert retrieved due to AE and for those with the insert retrieved for a reason other than AE within the MVI and DVI groups ( Table 2 ). Medical conditions as the primary reason for IOL, in particular hypertensive disorders, were more common for those with the insert retrieved due to AE in the DVI group. The multiple logistic regression analysis showed that the induction agent, DVI or MVI, was the only significant predictor of an AE as the primary reason for insert retrieval (P < 0.001), with a higher frequency in those assigned to the MVI group compared with those who had received DVI. None of the baseline clinical characteristics or demographics was shown to be a predictor of an AE as the primary reason for insert retrieval.
Time frame for intrapartum adverse events leading to vaginal insert retrieval
The overall median time from vaginal insert administration to onset of the AE leading to retrieval was shorter for women induced with MVI than for women induced with DVI (6 hours 45 minutes versus 9 hours 41 minutes, respectively; P = 0.002). The median time from insert One DVI subject had two AEs listed as reasons for vaginal insert retrieval (category II FHR and uterine hypertonus). *P < 0.001 between treatment groups; two-sided P-value was obtained from a Fisher's exact test of difference in incidence of IPAE as primary reason for removal versus all other reasons for insert retrieval. †Uterine tachysystole was defined as uterine activity of more than 5 contractions in a 10-minute window, averaged over three consecutive 10-minute periods (i.e. ≥18 contractions in 30 minutes, with each 10-minute period having at least 6 contractions). The contractions must have been of adequate intensity and duration, i.e. moderate intensity and duration ≥45 seconds, in order for the uterine activity to be characterized as tachysystole. ‡FHR involvement was defined as late decelerations, bradycardia or prolonged decelerations. Characteristics of decelerations were defined according to ACOG 2009 8 and Macones et al. 9 §Antepartum haemorrhage, n = 1 for MVI; arrested labour, n = 1 for DVI; puerperal pyrexia, n = 1 for MVI; premature separation of placenta, n = 1 for MVI; oedema genital, n = 1 for DVI; hypertension, n = 1 for MVI; superventricular tachycardia, n = 1 for DVI; fetal malpresentation, n = 2 for MVI.
-Retrieval was at the discretion of the treating clinician taking into account the clinical situation (i.e. when the event did not fit into the strictly defined AE category as described above 
Caesarean deliveries
The majority of women with insert retrieved due to AE were delivered by caesarean in both treatment groups (MVI: 44/77 (57.1%); DVI: 19/27 (70.4%)); however, this outcome represents a relatively small proportion of women in either treatment group for the overall study population (6.5% (44/678) and 2.8% (19/680), respectively). Caesarean delivery rates after specific AEs necessitating insert retrieval are listed in Table 2 , and are shown in Figures S1 and S2. The primary reasons for caesarean deliveries for each subgroup are listed in Table 3 .
Time to caesarean delivery
Median times from insert retrieval to caesarean delivery are presented in Table S1 . The majority of caesarean deliveries were performed at least several hours after insert retrieval due to AE (Figure 1 ).
Time to vaginal delivery
Median times from insert retrieval to vaginal delivery in both groups were similar for women who had the insert retrieved due to AE compared with those who had the insert retrieved due to reasons other than AEs (Table S1 ).
Neonatal outcomes
No neonatal deaths were reported during the study. A total of 8/77 (10.4%) and 1/27 (3.7%) neonates of women with the insert retrieved due to AE were admitted to NICU in the MVI and DVI groups, respectively (P = 0.440). In context, 53/601 (8.8%) and 70/653 (10.7%) neonates of women in the MVI and DVI groups with the insert retrieved for a reason other than AE were admitted to NICU. All neonates were discharged from NICU in good health.
For neonates of women with insert retrieved due to AE, low Apgar score (<7) at 5 minutes occurred in 4/77 (5.2%) 
Other clinical outcomes
Other safety outcomes are presented in Table 3 .
Discussion
The aim of this current investigation is to understand better the clinical implications of stopping prostaglandin administration by retrieving a prostaglandin vaginal insert during the labour induction process when an important complication occurred, as protocol stipulated, in the EXPE-DITE trial. The Phase III trial EXPEDITE studied the retrievable vaginal inserts, MVI and DVI, in a randomised double-blind fashion, from which data have been extracted for this post hoc investigation.
Main findings
Significantly more women induced with MVI experienced AEs that required protocol-specified insert retrieval compared with DVI. AEs that required retrieval were more likely to occur sooner after the start of induction with MVI than DVI. The most frequent AEs prompting retrieval in Category II/III FHR patterns may be less frequently drugrelated, as evidenced by most women who had retrieval due to a category II/III FHR pattern AE were delivered by caesarean for the same reason. Having to remove an insert due to a category II/III FHR pattern may thus indicate the presence of a fetus responding unfavourably to effective uterine contractions. Category II/III FHR pattern as the primary reason for caesarean delivery was more frequent among women with insert retrieved due to AE than among those with retrieval for reasons other than AE: 19/77 women (24.7%) versus 46/601 (7.7%) for MVI and 14/27 (51.9%) versus 30/653 (4.6%) for DVI even if most caesareans took place many hours after the insert removal.
Retrieval of DVI at the occurrence of uterine tachysystole (hyperstimulation) with FHR changes was associated with a rapid resolution of the event; in the DVI group, there were no caesarean deliveries due to uterine tachysystole with FHR changes, no indication of neonatal morbidity, and no increase in duration of time to delivery compared with those exposed to DVI with the insert removed for a reason other than AE.
Managing cases of uterine tachysystole with FHR changes is more challenging for misoprostol than dinoprostone due to the longer half-life of misoprostol (approximately 40 minutes for misoprostol 7 compared with approximately 3 minutes for dinoprostone 6 ). However, the prescribing information for the MVI states that, among other reasons for retrieval, the insert should be retrieved if uterine contractions are prolonged or excessive and if there is evidence of fetal compromise. Whether the opportunity to stop misoprostol administration in such cases, as is possible with MVI retrieval, offers a safety advantage over intermittent administration of larger, non-retrievable doses of misoprostol is a relevant hypothesis but would require comparison in a head-to-head clinical trial.
Strengths and limitations
The primary strength of the investigation is the design of the EXPEDITE trial upon which the analyses were extracted: a large, prospective, multi-centre, randomised, double-blind trial conducted according to stringent regulatory requirements. Definitions of key events such as uterine tachysystole with FHR involvement were prespecified. Moreover, data collection was closely monitored and, critical for the current analyses, AEs were recorded with start and stop times.
The limitations are that these analyses were conducted post hoc and the EXPEDITE trial was not designed or powered to study the subgroup analyses which are the focus of this investigation. As such, the results must be interpreted cautiously, particularly as the subgroups of interest (those who had experienced a predefined AE that required retrieval) made up less than 10% of the total study population and were defined by post-treatment characteristics. Furthermore, as these analyses were exploratory, all analyses have been presented without adjustment for multiple comparisons. Another limitation inherent in the conditions for the investigation is that it is not possible to know what the maternal and neonatal outcomes would have been without the possibility to retrieve the induction agent. Finally, although there were strict definitions for AEs necessitating insert retrieval that were prespecified in the EXPEDITE trial protocol, these definitions are not necessarily the same as those used in other trials or consistent with those applied in various local guidelines.
Interpretation
To our knowledge, no previous publication has reported on the course of women undergoing IOL and their neonates following retrieval of a prostaglandin insert after the onset of an AE necessitating its removal. Information on AE times-to-resolution, caesarean deliveries and neonatal outcomes are lacking in the literature. In a Cochrane systematic review on the use of vaginal misoprostol for cervical ripening and IOL, incidences for uterine hyperstimulation with FHR changes are reported with a range of 0-42%. 3 The wide incidence range probably reflects differences with regard to dose, frequency of dosing, inclusion criteria and how uterine hyperstimulation with FHR changes were assessed. It is also possible that varying degrees of data monitoring have an impact on the recorded reporting rate of the events. The incidence of uterine tachysystole with FHR involvement that prompted removal of MVI, using a strict definition, was 5.3% in our investigation of the EXPEDITE data. This figure cannot be compared directly with the incidence figures in the Cochrane review as there is no information in the review on the incidences that prompted any kind of intervention, e.g. tocolysis, withholding of scheduled next dosing, oxygen administration, caesarean delivery, etc., which could have been used as a surrogate for comparison.
Overall conclusions
Overall, fewer than 10% of the EXPEDITE trial population had AEs necessitating MVI or DVI retrieval; these were significantly more common in women induced with MVI. The most frequent AEs leading to insert retrieval were uterine tachysystole with FHR involvement and category II/III FHR patterns. MVI or DVI retrieval due to AE did not lengthen time to delivery and did not increase the rate of NICU admissions compared with women whose inserts were removed for reasons other than AE.
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In this paper the investigators carry out a secondary sub-analysis of adverse event management of a randomised controlled trial of induction of labour, comparing retrievable preparations of misprostol [Prostaglandin E 1 (MVI)] and dinoprostone [Prostaglandin E 2 (DVI)]: two different agents with different potencies, half lives, and release times. Significantly more women receiving MVI had adverse events requiring removal of the insert and the events occurred in a shorter time. Resolution of tachysystole with fetal heart rate involvement after removal was quicker for DVI. Interestingly, the time for resolution of fetal heart rate abnormalities alone was greater than those associated with tachysystole. There was no difference in NICU admissions between the two arms of the study and all neonates were discharged from the NICU in good condition. Although a small overall proportion of both groups, each had a high percentage of caesarean deliveries after removal [MVI 44/77 (57.1%) and DVI 19/27 (70.4%)]. There was a similar time to vaginal delivery for those who had an insert removed.
Induction of labour is a common procedure with an obvious primary goal and a need for a robust safety profile. This being a study of adverse events, it is of clinical value. Elements considered in the choice of technique for induction include patient population, local logistical factors, and cost. There is a cornucopia of choice of technique for the obstetric provider including mechanical agents, low dose oxytocin intravenous infusion, and both oral and vaginal medications. Each comes with an individual silhouette regarding patient comfort, suitability for outpatient management, requirement for fetal monitoring, and provider control. It is the latter issue that can be a significant disadvantage of medications as, once taken, they may not be practically reversed in the occurrence of an adverse event. Hence the allure of a medication delivered by vaginal insert, as unwanted effects may be potentially abrogated by removal of the insert.
The most significant finding of this study may be the high rate of caesarean delivery in both groups after removal of the insert. Percentages here of 57 and 70 seem to question the whole principle of the use of a vaginal insert in this setting. Timing to onset of, duration of, and timing to resolution of adverse events are of interest for each preparation but are of limited clinical value. It is a little surprising to see dinoprostone having a higher caesarean delivery rate after removal of insert. This, as well as many of the other adverse event statistics are hard to explain scientifically in terms of the half life of either drug.
The negative delivery outcome statistics appearing to question the use of vaginal inserts in this application; one may ask whether this was a study of drug safety profile or an investigation of the insert delivery system? Suggestions for further study may include investigation of two different doses of misoprostol, both delivered by the insert method, or a comparison of the same dose of either of the drugs delivered transvaginally as either tablet or insert.
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